Answers are grounded in this paper and cite their sources.
Platelets are not true cells, but fragments of megakaryocytes. These fragments have a profound impact on hemostasis. Binding of platelets to damaged von Willebrand factor expressing endothelium initiates platelet adhesion. The platelet plug is formed by fibrinogen interaction with GPIIb/IIIa. Activation of the platelets in the plug triggers the coagulation cascade and the plug is stabilized by thrombin. At each step in this complicated reaction, inherited or acquired dysfunction may lead to impaired hemostasis and risk of bleeding. In order to examine why patients bleed, it is necessary to understand the biology of platelets reviewed by Kickler in this issue of the journal.1 Impaired hemostasis can be due to a decreased number of normal platelets as a result of impaired production in the bone marrow (i.e. chemotherapy-induced bone marrow failure in cancer patients), increased consumption of platelets (i.e. disseminated intravascular coagulation) or increased loss of platelets (i.e. massive bleeding). In all these situations, replacement of platelets by transfusion may be indicated. The transfusion trigger, the number of platelets in the patient at which a platelet transfusion should be given, has not been well documented, nor has the dosage of platelets to be given in each transfusion. Why is this of concern? Transfusion of platelets may have potentially life-threatening side effects. Bacterial contamination of the product is the most feared complication. Also, the cost of platelet products is high. As discussed by Collins et al.,2 the indication should be based on studies showing the risk of bleeding compared with the platelet count in the patient in different clinical situations. There are studies showing that a transfusion trigger at platelet count 10 × 109/L is safe, and in some centers the transfusion trigger is 5 × 109/L for prophylactic transfusions.3, 4 The increased use of platelet transfusion is, to a large extent, dependent upon the increased use of antiplatelet drugs in the treatment of coronary diseases, particularly in relation to surgical interventions. The treatment induces dysfunctional platelets but the platelet count does not necessarily change, and transfusion triggers based on platelet counts cannot be used. There is a need for objective transfusion triggers in patients with normal platelet counts but impaired platelet function. Several systems for point-of-care measurement of platelet function are on the market. As discussed by Tanaka,5 the use of such systems may give objective indications for platelet transfusion and limit the use of platelet transfusions to situation where the patients will benefit from the transfusion. In order to implement evidence-based transfusion practices, relevant experimental transfusion studies must be performed. Heddle et al.6 give an overview of how to design, implement and perform clinical studies related to platelet transfusions. The endpoints in such studies must be chosen carefully. From a study design point of view, bleeding would be the ideal endpoint, but from the patient and ethical point of view, bleeding should be avoided. Surrogate endpoints must be chosen and such endpoints may limit the value of the results and make interpretations more difficult. Skogen and Husebekk7address the challenge of efficient transfusion therapy in patients with alloantibodies to platelet antigens. These antibodies can be directed toward AB blood type antigens, human leukemia antigens (HLA) or human platelet antigens (HPA). Two strategies can be chosen in order to find compatible platelets for transfusion. One strategy is to transfuse typed and matched products from the inventory. This is often not achievable because few blood banks have access to both HLA- and HPA-typed donors. The other strategy is crossmatching without considering the specificity of the antibodies. Both strategies require follow-up of the effect of transfusion with measurement of platelet increment. Strategy number two is simple and will in the majority of cases lead to successful transfusion results. Transmission of infectious diseases in blood products is the most feared side effect of transfusion. As platelets are stored at room temperature, bacterial contamination and growth are reported, in some cases resulting in sepsis or fatal outcome of transfusions. McCullough8 discusses the use of pathogen inactivation of platelet products. Pathogen inactivation is based on the principle of RNA and DNA nucleotide crossbinding induced by either amotosalen or riboflavin in combination with UV irradiation. The treatment of platelet concentrates does not significantly reduce the quality of the products, gives a sufficient reduction in all pathogens tested, has few if any side effects and will prevent transfusion-associated graft-versus-host disease because T cells cannot proliferate after the inactivation procedure. Why are these methods not included as routine treatment of all platelet products? The lack of implementation is first and foremost due to the cost of the procedure. The procedure is not available for red cell concentrates and until this is the case, testing for the usual infectious agents must be performed. This means that the cost of pathogen inactivation adds to the cost of testing. In countries where contamination is a minimal health problem, the cost of the procedure does not match the benefit. In countries where the benefit would be considerable, the cost is still too high. The idea of pathogen inactivation is exciting. In the future, this idea should be implemented in transfusion services in a cost-effective way. Platelet substitutes for clinical use inducing adhesion, aggregation, secretion, procoagulant activity and retraction are unlikely to be made outside the bone marrow.9 Platelets have short shelf life, and the most promising results making platelets easier to store for longer periods of time is cold storage with preserved function of the platelets.10 Efforts have been made to induce a more efficient thrombopoiesis in the bone marrow by treating the patient with thrombopoietin or thrombopoietin receptor agonists. Also, certain drugs can induce stabilization and retraction of the platelet plug and more efficient hemostasis with a limited number of platelets. The art of platelet transfusion remains to be a battle against hemorrhage, substituting the patients with enough platelets and procoagulant factors to maintain hemostasis, avoid harmful side effects and stimulate the natural production of enough platelets and other factors of importance for efficient hemostasis. In most cases we should be able to win this battle! I would like to thank the authors for their contributions to this issue dedicated to platelets.
No takes yet. Share an insight, caveat, or question.
Anne Husebekk (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: